Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab

Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up

(2013) Eva L Kneepkens et al.   ANNALS OF THE RHEUMATIC DISEASES

Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort

(2013) K. Danielsen et al.   BRITISH JOURNAL OF DERMATOLOGY

Rationale for treating primary Sjögren’s syndrome patients with an anti-CD6 monoclonal antibody (Itolizumab)

(2013) Christelle Le Dantec et al.   IMMUNOLOGIC RESEARCH

Anti-adalimumab and anti-infliximab antibodies developed in psoriasis vulgaris patients reduced the efficacy of biologics: Report of two cases

(2013) Yuka Matsumoto et al.   JOURNAL OF DERMATOLOGY

Comparative Efficacy of Biologics in Psoriasis

(2012) Iris H. Kim et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Anticorps anti-médicament, auto-anticorps et traitements biologiques du psoriasis

(2012) D. Jullien   ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE

Immunogenicity and autoimmunity during anti-TNF therapy

(2012) F. Atzeni et al.   AUTOIMMUNITY REVIEWS

Biological properties and regulation of IL-10 related cytokines and their contribution to autoimmune disease and tissue injury

(2012) S.R. Hofmann et al.   CLINICAL IMMUNOLOGY

A Prospective, Randomized, Placebo-Controlled Study to Identify Biomarkers Associated with Active Treatment in Psoriatic Arthritis: Effects of Adalimumab Treatment on Lesional and Nonlesional Skin

(2012) Marjan de Groot et al.   DERMATOLOGY

Sleep Loss and Cytokines Levels in an Experimental Model of Psoriasis

(2012) Camila Hirotsu et al.   PLoS One

Regulation and Functions of the IL-10 Family of Cytokines in Inflammation and Disease

(2011) Wenjun Ouyang et al.   Annual Review of Immunology

What’s new in psoriasis? An analysis of guidelines and systematic reviews published in 2009-2010

(2011) A. C. Foulkes et al.   CLINICAL AND EXPERIMENTAL DERMATOLOGY

Interpretation of cellular proliferation data: Avoid the panglossian

(2011) Mario Roederer   CYTOMETRY PART A

IL-8, IL-12 and IL-10 cytokines generation by neutrophils, fibroblasts and neutrophils- fibroblasts interaction in psoriasis

(2010) E Glowacka et al.   Advances in Medical Sciences

Imunopatogênese da psoríase

(2010) Ana Paula Galli Sanchez   ANAIS BRASILEIROS DE DERMATOLOGIA

CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction

(2010) P. Nair et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Clinically validated approaches to the treatment of autoimmune diseases

(2010) Percy H Carter et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Cell type-specific regulation of IL-10 expression in inflammation and disease

(2010) Christian M. Hedrich et al.   IMMUNOLOGIC RESEARCH

Aberrant expression of CD6 on B-cell subsets from patients with Sjögren’s syndrome

(2010) Ruby Alonso et al.   JOURNAL OF AUTOIMMUNITY

Positive treatment effects of ustekinumab in psoriasis: Analysis of lesional and systemic parameters

(2010) Manjula REDDY et al.   JOURNAL OF DERMATOLOGY

Validation of the CD6 and TNFRSF1A loci as risk factors for multiple sclerosis in Spain

(2010) Bhairavi Swaminathan et al.   JOURNAL OF NEUROIMMUNOLOGY

Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?

(2009) Eihab A. Alwawi et al.   Dermatologic Therapy

Multiple sclerosis susceptibility alleles in African Americans

(2009) B A Johnson et al.   GENES AND IMMUNITY

Psoriasis

(2009) Frank O. Nestle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Soluble human leukocyte antigen-G and interleukin-10 levels in plasma of psoriatic patients: preliminary study on a possible correlation between generalized immune status, treatments and disease

(2008) Alessandro Borghi et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Towards the Definition of a Chimpanzee and Human Conserved CD6 Domain 1 Epitope Recognized by T1 Monoclonal Antibody

(2008) Ruby Alonso et al.   HYBRIDOMA

Comprehensive biomarker monitoring in cytokine therapy: heterogeneous, time-dependent, and persisting immune effects of interleukin-10 application in psoriasis

(2008) Wolf-Dietrich Döcke et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET